The effect of Ghost oil on the treatment and relief of pain caused by diabetic neuropathy

The effect of Ghost oil on the treatment and relief of pain caused by diabetic neuropathy in a double-blind, parallel-controlled randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220305054184N2

Enrollment

Registered

2022-07-15

Start date

2022-08-23

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic neuropathy. Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy

Interventions

Intervention 1: Intervention group: For one month, in the intervention group, Gabapentin 100 mg capsules will be used once a day and Ghost oil (made by Bo Ali Daru Company) will be rubbed twice a day,

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: The main complaint of tingling Pain in the distal region of the lower limb for at least 3 months Clinical diagnosis of painful diabetic poly neuropathy plus a minimum score equal to or higher than 4 in the clinical evaluation of diabetic neuropathy (DN4 – Questionnaire) History of type 2 diabetes for at least 3 years Age over 18 years Chronic diabetic neuropathy

Exclusion criteria

Exclusion criteria: Lower limb pain caused by other diseases such as peripheral vascular disease and radiculopathy History of skin allergies to herbs Diabetic foot ulcers Taking other medications to treat diabetic neuropathy Drug addiction Taking anticoagulants Fractures and traumatic injuries lead to sensory and motor injuries in the lower extremities Autoimmune diseases (rheumatism and MS) History of hereditary neuropathies or underlying diseases that cause neuropathy such as chronic uremia lower limb amputation

Design outcomes

Primary

Measure	Time frame
Pain score. Timepoint: In the present study, the time intervals for measuring the pain score variable would be before the start of the study and again one month after treatment in each group. Method of measurement: McGill Questionnaire.;Quality of Life. Timepoint: In the present study, the time periods for measuring the quality of life variable would be before the start of the study and again one month after treatment in each group. Method of measurement: World Health Organization Quality of Life Questionnaire (WHOQOL-BREF).	—

Measure

Time frame

Pain score. Timepoint: In the present study, the time intervals for measuring the pain score variable would be before the start of the study and again one month after treatment in each group. Method of measurement: McGill Questionnaire.;Quality of Life. Timepoint: In the present study, the time periods for measuring the quality of life variable would be before the start of the study and again one month after treatment in each group. Method of measurement: World Health Organization Quality of Life Questionnaire (WHOQOL-BREF).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Fatemeh Haidarpour

Kermanshah University of Medical Sciences

FATEMEH_HYDARPUR@yahoo.com+98 83 3427 6473

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026